Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Up to $34.89

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $34.89, but opened at $36.51. Collegium Pharmaceutical shares last traded at $37.39, with a volume of 68,130 shares.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on COLL. Needham & Company LLC restated a “hold” rating on shares of Collegium Pharmaceutical in a research report on Tuesday. Piper Sandler downgraded shares of Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 price target for the company. in a research report on Friday, May 10th. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 1st. Jefferies Financial Group upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and upped their price target for the company from $41.00 to $44.00 in a research report on Friday, June 7th. Finally, HC Wainwright upgraded shares of Collegium Pharmaceutical from a “neutral” rating to a “buy” rating and set a $47.00 price target for the company in a research report on Tuesday. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Collegium Pharmaceutical has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Collegium Pharmaceutical Stock Performance

The company has a market cap of $1.25 billion, a PE ratio of 15.63 and a beta of 0.93. The company has a debt-to-equity ratio of 1.98, a quick ratio of 1.14 and a current ratio of 1.21. The stock’s 50-day simple moving average is $32.65 and its 200 day simple moving average is $34.63.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported $1.32 EPS for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.04). The firm had revenue of $144.92 million for the quarter, compared to analysts’ expectations of $147.04 million. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. As a group, equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.68 EPS for the current year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 19,710 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $34.21, for a total transaction of $674,279.10. Following the completion of the transaction, the chief financial officer now owns 130,845 shares in the company, valued at approximately $4,476,207.45. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, EVP Scott Dreyer sold 56,807 shares of the company’s stock in a transaction on Friday, May 24th. The shares were sold at an average price of $33.98, for a total transaction of $1,930,301.86. Following the transaction, the executive vice president now directly owns 105,902 shares of the company’s stock, valued at approximately $3,598,549.96. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Colleen Tupper sold 19,710 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total transaction of $674,279.10. Following the transaction, the chief financial officer now directly owns 130,845 shares in the company, valued at $4,476,207.45. The disclosure for this sale can be found here. In the last quarter, insiders sold 105,502 shares of company stock worth $3,540,796. 3.98% of the stock is owned by insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

Institutional investors and hedge funds have recently made changes to their positions in the stock. Gladius Capital Management LP acquired a new position in shares of Collegium Pharmaceutical during the 2nd quarter worth $32,000. Principal Securities Inc. acquired a new stake in Collegium Pharmaceutical in the 4th quarter valued at about $40,000. China Universal Asset Management Co. Ltd. grew its stake in Collegium Pharmaceutical by 320.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,776 shares of the specialty pharmaceutical company’s stock valued at $116,000 after acquiring an additional 2,877 shares during the last quarter. Assetmark Inc. grew its stake in Collegium Pharmaceutical by 25.5% in the 4th quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock valued at $168,000 after acquiring an additional 1,108 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC acquired a new stake in Collegium Pharmaceutical in the 1st quarter valued at about $204,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.